Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease
Open Access
- 23 August 2012
- journal article
- Published by Springer Nature in BMC Nephrology
- Vol. 13 (1) , 89
Abstract
Background: The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in high risk type 2 diabetes patients, the effect of dual RAAS inhibition in patients with non-DM CKD is unclear. The aim of this study was to evaluate the potential renoprotective effect of add-on direct renin inhibitor in non-DM CKD patients. Methods: We retrospectively enrolled 189 non-DM CKD patients who had been taking angiotensin II receptor blockers (ARBs) for more than six months. Patients were divided into an add-on aliskiren group and an ARB monotherapy group. The primary outcomes were a decline in glomerular filtration rate (GFR) and a reduction in urinary protein-to-creatinine ratio at six months. Results: The baseline characteristics of the two groups were similar. Aliskiren 150 mg daily reduced the urinary protein-to-creatinine ratio by 26% (95% confidence interval, 15 to 37%; p < 0.001). The decline in GFR was smaller in the add-on aliskiren group (−2.1 vs. -4.0 ml/min, p = 0.038). Add-on aliskiren had a neutral effect on serum potassium in the non-DM CKD patients. In subgroup analysis, the proteinuria-reducing effect of aliskiren was more prominent in patients with a GFR less than 60 ml/min, and in patients with a urinary protein-to-creatinine ratio greater than 1.8. The effect of aliskiren in retarding the decline in GFR was more prominent in patients with hypertensive nephropathy than in those with glomerulonephritis. Conclusion: Add-on direct renin inhibitor aliskiren (150 mg daily) safely reduced proteinuria and attenuated the decline in GFR in the non-DM CKD patients who were receiving ARBs.Keywords
This publication has 33 references indexed in Scilit:
- Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury—beyond the direct renin inhibitionHypertension Research, 2011
- ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trialClinical Nephrology, 2011
- The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney diseaseBMC Nephrology, 2011
- Aliskiren Ameliorates Renal Inflammation and Fibrosis Induced by Unilateral Ureteral Obstruction in MiceJournal of Urology, 2011
- New roles for renin and prorenin in heart failure and cardiorenal crosstalkHeart Failure Reviews, 2011
- A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskirenAmerican Journal of Physiology-Renal Physiology, 2010
- Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and NephropathyDiabetes Care, 2010
- Challenging chronic kidney disease: Experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and AustraliaNephrology, 2010
- Chronic kidney disease care program improves quality of pre‐end‐stage renal disease care and reduces medical costsNephrology, 2010
- Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 1999